ABLS - ETF AI Analysis
Top Page
Abacus FCF Small Cap Leaders ETF (ABLS)
ABLS, the Abacus FCF Small Cap Leaders ETF, has an overall rating that reflects a mix of strong, cash-generating small-cap companies alongside a few more challenged names. High-quality holdings like Qualys and Harmony Biosciences support the fund’s rating with solid financial performance, positive earnings commentary, and good growth prospects, while weaker positions such as Oscar Health and Appian, which face profitability and valuation issues, weigh it down. The main risk is that several holdings show bearish or mixed technical trends and, in some cases, high leverage, which can increase volatility for investors.
ABLS vs. SPDR S&P 500 ETF (SPY)
- AUM
- 466.20K
- Region
- North America
- Expense Ratio
- 0.39%
- Beta
- 0.72
- Issuer
- Abacus
- Inception Date
- Feb 18, 2025
- Dividend Yield
- 12.73%
- Asset Class
- Equity
- Index Tracked
- Abacus FCF Small Cap Leaders Index - Benchmark TR Gross
ABLS Summary
Abacus FCF Small Cap Leaders ETF (ABLS) is a fund that follows the Abacus FCF Small Cap Leaders Index, focusing on smaller U.S. companies with strong profits and cash flow. It spreads your money across different areas like health care, technology, and financials. Some of its holdings include Oscar Health and Appian, along with other lesser-known but financially solid businesses. Someone might invest in ABLS to tap into the growth potential of small companies while still being diversified across sectors. A key risk is that small-cap stocks can be more volatile, so the ETF’s price can move up and down sharply with the market.
How much will it cost me?
This ETF has an expense ratio of 0.39%, which means you’ll pay about $3.90 per year for every $1,000 invested. That cost is a bit higher than many broad, passively managed index ETFs, likely because it focuses on a more specialized group of small-cap companies with strong financial metrics.
What would affect this ETF?
ABLS could benefit if the U.S. economy grows steadily, supporting small-cap companies in health care, technology, and financials, and if strong cash flow and profitability remain rewarded by investors. On the downside, rising interest rates, economic slowdowns, or new regulations affecting health care, tech, or financial firms—especially its top holdings like Oscar Health, Qualys, and Artisan Partners—could hurt performance more than larger, more diversified ETFs.
ABLS Top 10 Holdings
ABLS is a U.S.-only small-cap fund with a clear tilt toward health care and tech, and a few financial names in the mix. Cybersecurity player Qualys and software name Appian have been rising and are doing much of the heavy lifting, while health care names like Healthcare Services and Harmony Biosciences are adding steady support. On the flip side, Argan has been losing altitude and Artisan Partners looks sluggish, acting as mild brakes on performance. Overall, the fund is concentrated in a handful of small-cap standouts rather than household names.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 AGX | Argan | 7.50% | $34.97K | $4.83B | 15.35% | 73Outperform |
 QLYS | Qualys | 5.68% | $26.48K | $7.75B | 81.05% | 78Outperform |
 OSCR | Oscar Health | 5.16% | $24.05K | $9.38B | 67.88% | 49Neutral |
 APPN | Appian | 4.19% | $19.53K | $3.52B | 64.71% | 58Neutral |
 APAM | Artisan Partners | 4.22% | $19.65K | $2.96B | -15.73% | 73Outperform |
 ENVA | Enova International | 3.96% | $18.47K | $4.26B | 46.02% | 71Outperform |
 HCSG | Healthcare Services | 4.01% | $18.71K | $1.65B | 33.92% | 72Outperform |
 HRMY | Harmony Biosciences Holdings | 3.58% | $16.71K | $2.26B | 34.12% | 81Outperform |
 WK | Workiva | 3.07% | $14.30K | $4.55B | -3.37% | 52Neutral |
 KTB | Kontoor Brands | 3.17% | $14.79K | $4.06B | -8.50% | 66Neutral |
ABLS Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For ABLS, the sentiment is Positive. The current price of 22.43 is above the 20-day moving average (MA) of 21.61, above the 50-day MA of 21.53, and above the 200-day MA of 20.81, indicating a bullish trend. The MACD of 0.31 indicates Negative momentum. The RSI at 62.59 is Neutral, neither overbought nor oversold. The STOCH value of 91.53 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ABLS.
ABLS Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| ABLS | $22.43 | $23.00(2.55% Upside) | $466.20K | 0.39% | 68Neutral |
 RUSC | $36.75 | $50.00(36.04% Upside) | $85.25M | 0.64% | 64Neutral |
 AIMS | $26.93 | $34.54(28.30% Upside) | $84.74M | 0.75% | 65Neutral |
 BKSE | $42.73 | $52.82(23.60% Upside) | $83.90M | 0.04% | 65Neutral |
 STXK | $36.85 | $46.08(25.04% Upside) | $79.32M | 0.18% | 65Neutral |
 SYZ | $29.36 | $36.87(25.58% Upside) | $63.23M | 0.61% | 66Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ABLS | Abacus FCF Small Cap Leaders ETF | 22.43 | 2.40 | 12.00% | |
| RUSC | US Small Cap Equity Active ETF | 36.75 | 6.32 | 20.75% | |
| AIMS | Acuitas Small Cap Active ETF | 26.93 | 1.75 | 6.93% | |
| BKSE | BNY Mellon US Small Cap Core Equity ETF | 42.73 | 6.40 | 17.61% | |
| STXK | Strive 2000 ETF | 36.85 | 4.25 | 13.05% | |
| SYZ | Lazard US Systematic Small Cap Equity ETF | 29.36 | 5.08 | 20.93% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.